Oral Solid Dose Oncology CDMO Market Size, Share, and Trends 2025 to 2034

Oral Solid Dose Oncology CDMO Market (By Service type: Formulation & Process Development, Analytical Development & Testing, Commercial Manufacturing, High-Potency, Packaging & Secondary Operations; By process / Technology: Granulation Technologies, Direct Compression; By product type / Molecule Class: Small-molecule targeted oncology agents, Hormonal & supportive oncology small molecules; By dosage form / Release Profile: Immediate Release, Delayed / Enteric Release; By API Potency / Safety Classification: Non-HPAP, Low-to-moderate potency oncology APIs; By Customer type: Large pharma, Generic manufacturers, Specialty companie; By Contract / Commercial Model: Fee-for-service, Risk-sharing, Toll manufacturing; By Scale / Capacity: Laboratory / R&D scale, Clinical scale) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034

Last Updated : October 2025  |  Report Code : 7007  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Oral Solid Dose Oncology CDMO Market, By Service type

7.1. Oral Solid Dose Oncology CDMO Market, by Service type

7.1.1. Formulation & Process Development

7.1.1.1. Market Revenue and Forecast

7.1.2. Analytical Development & Testing

7.1.2.1. Market Revenue and Forecast

7.1.3. Clinical Manufacturing (GMP)

7.1.3.1. Market Revenue and Forecast

7.1.5. Commercial Manufacturing (GMP)

7.1.5.1. Market Revenue and Forecast

7.1.6. High-Potency & Cytotoxic Handling Services

7.1.6.1. Market Revenue and Forecast

7.1.7. Packaging & Secondary Operations

7.1.7.1. Market Revenue and Forecast

7.1.8. Regulatory & Quality Services

7.1.8.1. Market Revenue and Forecast

7.1.9. Supply Chain & Logistics

7.1.9.1. Market Revenue and Forecast

Chapter 8. Global Oral Solid Dose Oncology CDMO Market, By Process / Technology

8.1. Oral Solid Dose Oncology CDMO Market, by Process / Technology

8.1.1. Granulation Technologies

8.1.1.1. Market Revenue and Forecast

8.1.2. Direct Compression

8.1.2.1. Market Revenue and Forecast

8.1.3. Encapsulation & Fill Technologies

8.1.3.1. Market Revenue and Forecast

8.1.4. Oral Thin Film / ODT / Chewable Technologies

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Oral Solid Dose Oncology CDMO Market, By Product type / Molecule Class

9.1. Oral Solid Dose Oncology CDMO Market, by Product type / Molecule Class

9.1.1. Small-molecule targeted oncology agents (oral TKIs, kinase inhibitors)

9.1.1.1. Market Revenue and Forecast

9.1.2. Cytotoxic / Cytostatic agents (oral chemotherapeutics)

9.1.2.1. Market Revenue and Forecast

9.1.3. Hormonal & supportive oncology small molecules

9.1.3.1. Market Revenue and Forecast

9.1.4. Orally-administered ADC precursors / prodrugs

9.1.4.1. Market Revenue and Forecast

9.1.5. High-Potency Active Pharmaceutical Ingredients (HPAPIs)

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Oral Solid Dose Oncology CDMO Market, By Dosage form / Release Profile

10.1. Oral Solid Dose Oncology CDMO Market, by Dosage form / Release Profile

10.1.1. Immediate Release (IR) tablets & capsules

10.1.1.1. Market Revenue and Forecast

10.1.2. Modified / Controlled Release (MR/CR)

10.1.2.1. Market Revenue and Forecast

10.1.3. Delayed / Enteric Release

10.1.3.1. Market Revenue and Forecast

10.1.4. Orally Disintegrating Tablets (ODT) / Orally Thin Films

10.1.4.1. Market Revenue and Forecast

10.1.5. Multiparticulate systems (pellets, granules in capsules)

10.1.5.1. Market Revenue and Forecast

Chapter 11. Global Oral Solid Dose Oncology CDMO Market, By API Potency / Safety Classification

11.1. Oral Solid Dose Oncology CDMO Market, by API Potency / Safety Classification

11.1.1. Non-HPAPI (standard small molecules)

11.1.1.1. Market Revenue and Forecast

11.1.2. Low-to-moderate potency oncology APIs

11.1.2.1. Market Revenue and Forecast

11.1.3. High-Potency APIs (HPAPIs) / Cytotoxics

11.1.3.1. Market Revenue and Forecast

11.1.4. Highly cytotoxic / controlled substances

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Oral Solid Dose Oncology CDMO Market, By Customer type

12.1. Oral Solid Dose Oncology CDMO Market, by Customer type

12.1.1. Large pharma (in-house programs outsourced for scale/compliance)

12.1.1.1. Market Revenue and Forecast

12.1.2. Biotech / small & mid-size pharma (core CDMO customers for end-to-end development)

12.1.2.1. Market Revenue and Forecast

12.1.3. Generic manufacturers (ANDAs for oncology generics)

12.1.3.1. Market Revenue and Forecast

12.1.4. Specialty companies (HPAPI-focused, orphan oncology players)

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Oral Solid Dose Oncology CDMO Market, By Contract / Commercial Model

13.1. Oral Solid Dose Oncology CDMO Market, by Contract / Commercial Model

13.1.1. Fee-for-service / time & materials

13.1.1.1. Market Revenue and Forecast

13.1.2. Fixed-price / turnkey (end-to-end) contracts

13.1.2.1. Market Revenue and Forecast

13.1.3. Risk-sharing / milestone-based agreements

13.1.3.1. Market Revenue and Forecast

13.1.4. Toll manufacturing / dedicated long-term agreements

13.1.4.1. Market Revenue and Forecast

Chapter 14. Global Oral Solid Dose Oncology CDMO Market, By Scale / Capacity

14.1. Oral Solid Dose Oncology CDMO Market, by Scale / Capacity

14.1.1. Laboratory / R&D scale (mg → g)

14.1.1.1. Market Revenue and Forecast

14.1.2. Pilot scale (100s g → kg)

14.1.2.1. Market Revenue and Forecast

14.1.3. Clinical scale (kg-level for Ph I–III)

14.1.3.1. Market Revenue and Forecast

14.1.4. Commercial scale (multi-tonne capability for blockbuster needs)

14.1.4.1. Market Revenue and Forecast

Chapter 15. Global Oral Solid Dose Oncology CDMO Market, By Analytical & Regulatory Support

15.1. Oral Solid Dose Oncology CDMO Market, by Analytical & Regulatory Support

15.1.1. Bioanalytical assays, PK/PD support

151.1.1. Market Revenue and Forecast

15.1.2. Stability program design & ICH studies

15.1.2.1. Market Revenue and Forecast

15.1.3. Regulatory filing support (CMC for IND/CTA/MAA/NDA/ANDA)

15.1.3.1. Market Revenue and Forecast

15.1.4. Method transfer & validation

15.1.4.1. Market Revenue and Forecast

Chapter 16. Global Oral Solid Dose Oncology CDMO Market, Regional Estimates and Trend Forecast

16.1. North America

16.1.1. Market Revenue and Forecast, by Service type

16.1.2. Market Revenue and Forecast, by Process / Technology

16.1.3. Market Revenue and Forecast, by Product type / Molecule Class

16.1.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.1.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.1.6. Market Revenue and Forecast, by Customer type

16.1.7. Market Revenue and Forecast, by Contract / Commercial Model

16.1.8. Market Revenue and Forecast, by Scale / Capacity

16.1.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.1.9. U.S.

16.1.9.1. Market Revenue and Forecast, by Service type

16.1.9.2. Market Revenue and Forecast, by Process / Technology

16.1.9.3. Market Revenue and Forecast, by Product type / Molecule Class

16.1.9.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.1.9.5.  Market Revenue and Forecast, by API Potency / Safety Classification

16.1.9.6. Market Revenue and Forecast, by Customer type

16.1.9.7. Market Revenue and Forecast, by Contract / Commercial Model

16.1.9.8. Market Revenue and Forecast, by Scale / Capacity

16.1.9.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.1.10. Rest of North America

16.1.10.1. Market Revenue and Forecast, by Service type

16.1.10.2. Market Revenue and Forecast, by Process / Technology

16.1.10.3. Market Revenue and Forecast, by Product type / Molecule Class

16.1.10.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.1.10.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.1.10.6. Market Revenue and Forecast, by Customer type

16.1.10.7. Market Revenue and Forecast, by Contract / Commercial Model

16.1.10.8. Market Revenue and Forecast, by Scale / Capacity

16.1.10.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.2. Europe

16.2.1. Market Revenue and Forecast, by Service type

16.2.2. Market Revenue and Forecast, by Process / Technology

16.2.3. Market Revenue and Forecast, by Product type / Molecule Class

16.2.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.2.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.2.6. Market Revenue and Forecast, by Customer type

16.2.7. Market Revenue and Forecast, by Contract / Commercial Model

16.2.8. Market Revenue and Forecast, by Scale / Capacity

16.2.9. Market Revenue and Forecast, by Analytical & Regulatory Support

15.2.9. UK

16.2.9.1. Market Revenue and Forecast, by Service type

16.2.9.2. Market Revenue and Forecast, by Process / Technology

16.2.9.3. Market Revenue and Forecast, by Product type / Molecule Class

16.2.9.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.2.9.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.2.9.6. Market Revenue and Forecast, by Customer type

16.2.9.7. Market Revenue and Forecast, by Contract / Commercial Model

16.2.9.8. Market Revenue and Forecast, by Scale / Capacity

16.2.9.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.2.10. Germany

16.2.10.1. Market Revenue and Forecast, by Service type

16.2.10.2. Market Revenue and Forecast, by Process / Technology

16.2.10.3. Market Revenue and Forecast, by Product type / Molecule Class

16.2.10.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.2.10.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.2.10.6. Market Revenue and Forecast, by Customer type

16.2.10.7. Market Revenue and Forecast, by Contract / Commercial Model

16.2.10.8. Market Revenue and Forecast, by Scale / Capacity

16.2.10.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.2.11.  France

16.2.11.1. Market Revenue and Forecast, by Service type

16.2.11.2. Market Revenue and Forecast, by Process / Technology

16.2.11.3. Market Revenue and Forecast, by Product type / Molecule Class

16.2.11.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.2.11.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.2.11.6. Market Revenue and Forecast, by Customer type

16.2.11.7. Market Revenue and Forecast, by Contract / Commercial Model

16.2.11.8. Market Revenue and Forecast, by Scale / Capacity

16.2.11.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.2.12. Rest of Europe

16.2.12.1. Market Revenue and Forecast, by Service type

16.2.12.2. Market Revenue and Forecast, by Process / Technology

16.2.12.3. Market Revenue and Forecast, by Product type / Molecule Class

16.2.12.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.2.12.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.2.12.6. Market Revenue and Forecast, by Customer type

16.2.12.7. Market Revenue and Forecast, by Contract / Commercial Model

16.2.12.8. Market Revenue and Forecast, by Scale / Capacity

16.2.12.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.3. APAC

16.3.1. Market Revenue and Forecast, by Service type

16.3.2. Market Revenue and Forecast, by Process / Technology

16.3.3. Market Revenue and Forecast, by Product type / Molecule Class

16.3.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.3.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.3.6. Market Revenue and Forecast, by Customer type

16.3.7. Market Revenue and Forecast, by Contract / Commercial Model

16.3.8. Market Revenue and Forecast, by Scale / Capacity

16.3.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.3.9. India

16.3.9.1. Market Revenue and Forecast, by Service type

16.3.9.2. Market Revenue and Forecast, by Process / Technology

16.3.9.3. Market Revenue and Forecast, by Product type / Molecule Class

16.3.9.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.3.9.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.3.9.6. Market Revenue and Forecast, by Customer type

16.3.9.7. Market Revenue and Forecast, by Contract / Commercial Model

16.3.9.8. Market Revenue and Forecast, by Scale / Capacity

16.3.9.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.3.10. China

16.3.10.1. Market Revenue and Forecast, by Service type

16.3.10.2. Market Revenue and Forecast, by Process / Technology

16.3.10.3. Market Revenue and Forecast, by Product type / Molecule Class

16.3.10.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.3.10.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.3.10.6. Market Revenue and Forecast, by Customer type

16.3.10.7. Market Revenue and Forecast, by Contract / Commercial Model

16.3.10.8. Market Revenue and Forecast, by Scale / Capacity

16.3.10.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.3.11. Japan

16.3.11.1. Market Revenue and Forecast, by Service type

16.3.11.2. Market Revenue and Forecast, by Process / Technology

16.3.11.3. Market Revenue and Forecast, by Product type / Molecule Class

16.3.11.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.3.11.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.3.11.6. Market Revenue and Forecast, by Customer type

16.3.11.7. Market Revenue and Forecast, by Contract / Commercial Model

16.3.11.8. Market Revenue and Forecast, by Scale / Capacity

16.3.11.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.3.12. Rest of APAC

16.3.12.1. Market Revenue and Forecast, by Service type

16.3.12.2. Market Revenue and Forecast, by Process / Technology

16.3.12.3. Market Revenue and Forecast, by Product type / Molecule Class

16.3.12.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.3.12.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.3.12.6. Market Revenue and Forecast, by Customer type

16.3.12.7. Market Revenue and Forecast, by Contract / Commercial Model

16.3.12.8. Market Revenue and Forecast, by Scale / Capacity

16.3.12.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.4. MEA

16.4.1. Market Revenue and Forecast, by Service type

16.4.2. Market Revenue and Forecast, by Process / Technology

16.4.3. Market Revenue and Forecast, by Product type / Molecule Class

16.4.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.4.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.4.6. Market Revenue and Forecast, by Customer type

16.4.7. Market Revenue and Forecast, by Contract / Commercial Model

16.4.8. Market Revenue and Forecast, by Scale / Capacity

16.4.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.4.9. GCC

16.4.9.1. Market Revenue and Forecast, by Service type

16.4.9.2. Market Revenue and Forecast, by Process / Technology

16.4.9.3. Market Revenue and Forecast, by Product type / Molecule Class

16.4.9.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.4.9.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.4.9.6. Market Revenue and Forecast, by Customer type

16.4.9.7. Market Revenue and Forecast, by Contract / Commercial Model

16.4.9.8. Market Revenue and Forecast, by Scale / Capacity

16.4.9.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.4.10. North Africa

16.4.10.1. Market Revenue and Forecast, by Service type

16.4.10.2. Market Revenue and Forecast, by Process / Technology

16.4.10.3. Market Revenue and Forecast, by Product type / Molecule Class

16.4.10.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.4.10.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.4.10.6. Market Revenue and Forecast, by Customer type

16.4.10.7. Market Revenue and Forecast, by Contract / Commercial Model

16.4.10.8. Market Revenue and Forecast, by Scale / Capacity

16.4.10.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.4.11. South Africa

16.4.11.1. Market Revenue and Forecast, by Service type

16.4.11.2. Market Revenue and Forecast, by Process / Technology

16.4.11.3. Market Revenue and Forecast, by Product type / Molecule Class

16.4.11.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.4.11.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.4.11.6. Market Revenue and Forecast, by Customer type

16.4.11.7. Market Revenue and Forecast, by Contract / Commercial Model

16.4.11.8. Market Revenue and Forecast, by Scale / Capacity

16.4.11.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.4.12. Rest of MEA

16.4.12.1. Market Revenue and Forecast, by Service type

16.4.12.2. Market Revenue and Forecast, by Process / Technology

16.4.12.3. Market Revenue and Forecast, by Product type / Molecule Class

16.4.12.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.4.12.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.4.12.6. Market Revenue and Forecast, by Customer type

16.4.12.7. Market Revenue and Forecast, by Contract / Commercial Model

16.4.12.8. Market Revenue and Forecast, by Scale / Capacity

16.4.12.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.5. Latin America

16.5.1. Market Revenue and Forecast, by Service type

16.5.2. Market Revenue and Forecast, by Process / Technology

16.5.3. Market Revenue and Forecast, by Product type / Molecule Class

16.5.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.5.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.5.6. Market Revenue and Forecast, by Customer type

16.5.7. Market Revenue and Forecast, by Contract / Commercial Model

16.5.8. Market Revenue and Forecast, by Scale / Capacity

16.5.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.5.9. Brazil

16.5.9.1. Market Revenue and Forecast, by Service type

16.5.9.2. Market Revenue and Forecast, by Process / Technology

16.5.9.3. Market Revenue and Forecast, by Product type / Molecule Class

16.5.9.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.5.9.5. Market Revenue and Forecast, by API Potency / Safety Classification

16.5.9.6. Market Revenue and Forecast, by Customer type

16.5.9.7. Market Revenue and Forecast, by Contract / Commercial Model

16.5.9.8. Market Revenue and Forecast, by Scale / Capacity

16.5.9.9. Market Revenue and Forecast, by Analytical & Regulatory Support

16.5.10.   Rest of LATAM

16.5.10.1. Market Revenue and Forecast, by Service type

16.5.10.2. Market Revenue and Forecast, by Process / Technology

16.5.10.3. Market Revenue and Forecast, by Product type / Molecule Class

16.5.10.4. Market Revenue and Forecast, by Dosage form / Release Profile

16.5.10.5. Market Revenue and Forecast, by API Potency / Safety Classification 

16.5.10.6. Market Revenue and Forecast, by Customer type

16.5.10.7. Market Revenue and Forecast, by Contract / Commercial Model

16.5.10.8. Market Revenue and Forecast, by Scale / Capacity

16.5.10.9. Market Revenue and Forecast, by Analytical & Regulatory Support

Chapter 17. Company Profiles

17.1. Fareva

17.1.1. Company Overview

17.1.2. Product Offerings

17.1.3. Financial Performance

17.1.4. Recent Initiatives

17.2. Cambrex

17.2.1. Company Overview

17.2.2. Product Offerings

17.2.3. Financial Performance

17.2.4. Recent Initiatives

17.3. Siegfried Group

17.3.1. Company Overview

17.3.2. Product Offerings

17.3.3. Financial Performance

17.3.4. Recent Initiatives

17.4. Aenova

17.4.1. Company Overview

17.4.2. Product Offerings

17.4.3. Financial Performance

17.4.4. Recent Initiatives

17.5. Alcami

17.5.1. Company Overview

17.5.2. Product Offerings

17.5.3. Financial Performance

17.5.4. Recent Initiatives

17.6. Evonik

17.6.1. Company Overview

17.6.2. Product Offerings

17.6.3. Financial Performance

17.6.4. Recent Initiatives

17.7. PCI Pharma Services

17.7.1. Company Overview

17.7.2. Product Offerings

17.7.3. Financial Performance

17.7.4. Recent Initiatives

17.8. Abbott

17.8.1. Company Overview

17.8.2. Product Offerings

17.8.3. Financial Performance

17.8.4. Recent Initiatives

17.9. Abbott

17.9.1. Company Overview

17.9.2. Product Offerings

17.9.3. Financial Performance

17.9.4. Recent Initiatives

17.10. Abbott

17.10.1. Company Overview

17.10.2. Product Offerings

17.10.3. Financial Performance

17.10.4. Recent Initiatives

Chapter 18. Research Methodology

18.7. Primary Research

18.7. Secondary Research

18.7. Assumptions

Chapter 19. Appendix

19.1. About Us

19.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The major players in the oral solid dose oncology CDMO market include Cambrex, Fareva, Siegfried Group, Aenova, Alcami, Evonik, and PCI Pharma Services.

The driving factors of the oral solid dose oncology CDMO market are the rising demand for effective cancer treatments in solid dosage forms.

North America region will lead the global oral solid dose oncology CDMO market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client